ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Cash-to-Debt : 7.67 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ACADIA Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.67.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ACADIA Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for ACADIA Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ACAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.72 Med: 5035.6 Max: No Debt
Current: 7.67

During the past 13 years, ACADIA Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 6.72. And the median was 5035.60.

ACAD's Cash-to-Debt is ranked better than
52.18% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs ACAD: 7.67

ACADIA Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for ACADIA Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ACADIA Pharmaceuticals Cash-to-Debt Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

71.20

12.76

8.08

6.72

7.67

ACADIA Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															6.72	6.65	6.38	6.06	7.67

Competitive Comparison of ACADIA Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cash-to-Debt falls into.

ACADIA Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ACADIA Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	438.865	/	(9.405	+	47.8)
	=	7.67

ACADIA Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	438.865	/	(9.405	+	47.8)
	=	7.67

ACADIA Pharmaceuticals (NAS:ACAD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ACADIA Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

DR6:Germany DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Executives

Austin D. Kim	officer: EVP & General Counsel	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan	officer: EVP, COO, Head of Commercial	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis	director, officer: PRESIDENT AND CEO	ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara	officer: Principal Accounting Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer	officer: Chief Financial Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson	officer: Executive VP, Research & Dev	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic	officer: EVP	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff	officer: EVP and CFO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang	officer: EVP AND CCO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller	officer: Controller & PAO	C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130